Thermo Fisher expands its Gibco Bacto CD portfolio with new formulations aimed at boosting E. coli-based plasmid DNA and protein production efficiency.

Rising demand for gene and cell therapies, expanding mRNA vaccine pipelines, and increasing investments in GMP-compliant manufacturing facilities are driving growth in the viral vectors and plasmid ...

Plasmid DNA is an essential part of cell and gene therapy products. It is utilized as a template vector for cell therapy and non-viral gene therapy and as a raw material to produce adeno-associated ...

Plasmid DNA lies at the heart of viral and mRNA vector production because it provides the coding sequences for gene-based advanced therapy medicinal products (ATMPs). Its manufacture is therefore ...

Researchers have developed PlasmidMaker, a versatile automated platform for plasmid design & construction. These circular DNA molecules are used by scientists to introduce new genes into a target ...

Success in gene and cell therapy is driving demand for plasmid DNA which is a key reagent to produce viral vectors, both for commercial products as well as the breadth of different vectors for the ...

The companies have signed an agreement for the production of two plasmids needed for the manufacture of CG01, a gene therapy for the treatment of drug-resistant focal epilepsy. Cobra Biologics, a ...

This guide provides an in-depth exploration of the essential role plasmids play in biotechnology and genetic engineering. From foundational concepts to the complexities of high-throughput production, ...

Thermo Fisher Scientific Inc., the world leader in serving science, today announced the launch of Gibco(TM) Bacto(TM) CD Supreme FPM Plus and Gibco(TM) Bacto(TM) CD Supreme Feed (2X), two ...